OrbiMed
New York Β· Pre-SeedβLate Stage
Investment thesis
OrbiMed's investment approach is grounded in the structural growth of global healthcare driven by demographic trends and scientific innovation in disease treatment. The firm believes the combination of healthcare's powerful growth profile, magnitude, and inherent complexity creates substantial investment opportunities across multiple asset classes and geographies. The firm seeks to build portfolio companies into market leaders while supporting responsible, sustainable growth that generates long-term shareholder value.
Source: firm website, verified Jul 20, 2026.
What they invest in
from 34 of 201 portfolio companiesBiotech Γ25Medical Devices Γ20Healthtech Γ13AI & Machine Learning Γ9Digital Health Γ6Deep Tech Γ4Enterprise Software Γ3SaaS Γ3
HQs:United StatesΓ10AustraliaΓ1United KingdomΓ1
Investments Β· showing 60 of 201
founders shown can be your intro pathAspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease. The company is a clinical-stage biotechnology firm focused on personalized neuron replacement therapies.
BiotechDeep TechDigital HealthMedical Devices<UNKNOWN>, US
AndrΓ©s Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions. The company uses advanced engineering of natural CRISPR systems to create targeted genetic medicines.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis. The treatments are performed in doctor's offices and operating rooms using a touch-screen console that delivers temperature-controlled radiofrequency therapy.
HealthtechMedical Devices
Matt Brokaw(CEO & President)
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases. The company uses data-driven approaches and bioinformatics to identify and develop its pipeline of aging-focused therapeutics.
BiotechHealthtechLongevity
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
BiotechHealthtech
Ken Song(Chairman, President and CEO)
Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families. The platform serves members seeking compassionate, personalized reproductive health support.
FemTechHealthtechSan Francisco, US
Convergent provides an AI simulation platform for enterprise training and skill development. The platform uses interactive avatars to enable employees across sales, support, HR, healthcare, compliance, and other functions to practice high-stakes conversations and workflows with real-time feedback and performance analytics.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach. The company targets therapeutics to improve treatment efficacy beyond current standards in immunology and fibrotic conditions.
AI & Machine LearningMedical Devices
Pinnacle provides an API for sending RCS, SMS, MMS, and iMessage messages with features like rich cards, carousels, and quick replies. The platform serves businesses of all sizes that need to send marketing campaigns, transactional alerts, and customer conversations at scale.
Developer ToolsE-commerceEnterprise SoftwareMarketing TechSaaSSan Francisco, US
Sean Roades(Founder)inIvan Zhang(Founder)inJustin Zheng(Co-founder)
Prelude Therapeutics develops precision oncology medicines, including selective KAT6A degraders, mutant-selective JAK2 inhibitors, and degrader antibody conjugates for cancer treatment. The company focuses on clinically validated targets with high unmet medical needs in oncology.
AI & Machine LearningBiotechMedical Devices
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.
AI & Machine LearningBiotechMedical Devices
Jeff
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices<UNKNOWN>, US
Sidewinder Bio develops next-generation bispecific antibody-drug conjugates (ADCs) designed to treat solid tumors with enhanced specificity for difficult-to-treat cancers. The company engineers therapies targeting receptor co-complexes to improve therapeutic window and tumor cell specificity.
BiotechMedical Devices
RarePath is a biotech platform that creates pathways for scientists to develop cures for rare and ultra-rare diseases by partnering with academic researchers, biotech firms, and patient foundations to fund, license, and commercialize therapies.
Biotech
ArriVent BioPharma develops innovative oncology therapeutics targeting cancer treatment. The company focuses on advancing these therapies toward global patient access.
BiotechMedical Devices
<UNKNOWN>Brent Rice(Chief Commercial Officer)
Congruence is a drug discovery company using protein dynamics, biophysics, machine learning, and computational chemistry to develop predictive models for disease correction. The company serves pharmaceutical and biotech organizations seeking accelerated and more accurate drug discovery processes.
AI & Machine LearningBiotech
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.
BiotechHealthtechMedical Devices
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need. The company engineers therapeutic medicines designed to deliver clinically differentiated outcomes for cancer patients.
BiotechMedical Devices
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs. The company is focused on rare genetic conditions including cystic fibrosis and primary ciliary dyskinesia.
AI & Machine LearningBiotechMedical Devices
Dr. Daniel J. Siegwart
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Averna Therapeutics develops non-viral gene delivery technology using lipid nanoparticles and engineered retrotransposons to safely insert genetic instructions into cells. The platform targets genetic medicine applications across a broad range of addressable diseases.
BiotechDeep TechMedical Devices
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions. The company focuses on improving the standard of care for patients with these disease types.
BiotechDigital HealthHealthtechMedical Devices
Frequently asked questions
- What stage does OrbiMed invest at?
- OrbiMed invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does OrbiMed focus on?
- OrbiMed focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is OrbiMed located?
- OrbiMed is headquartered in New York, US.
- Does OrbiMed lead rounds?
- Yes, OrbiMed leads investment rounds.
Similar investors
Data Collective identifies and supports ambitious company founders developing technology-driven solutions. The firm focuses on companies using innovation to restore predictability in an unstable world, with demonstrated expertise across clean energy, gene therapy, sustainable agriculture, and machine learning applications in healthcare.
Novo Holdings is a major life science investor managing approximately $14 billion in assets under management. The firm allocates a significant portion of its portfolio to direct life science investing across seed, venture, and principal investment stages, while also investing in equities, bonds, real estate, infrastructure, and private equity through its Capital Investments division.
Apple Tree Partners is a life sciences venture capital firm founded in 1999 that invests across multiple stages, from pre-commercial research ideas to mature companies approaching or achieving public markets.
Breyer Capital invests in breakthrough biomedical technologies, emerging models of care, and economic systems that drive sustainable healthcare transformation. The firm partners early and deeply with entrepreneurs across AI-first diagnostics, programmable medicines, data infrastructure, financial systems, clinician software, and novel care delivery models.
Google Ventures invests in innovative founders across diverse industries, focusing on companies where they can provide value across multiple stages and milestones through long-term relationships.